A ProspeCtive ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice
A ProspeCtive ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting.
Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world.
Participants will receive atogepant oral tablets as prescribed per standard clinical practice and will be followed for 2 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arizona 85013, United States
Los Angeles, California 90067-2001, United States
London, Ontario N6A 5W9, Canada
Kiel, Schleswig-Holstein 24105, Germany
Turin, Piedmont 10126, Italy
Pavia, 27100, Italy
Lausanne, Canton of Vaud 1011, Switzerland
Edinburgh, Edinburgh, City of EH4 2XU, United Kingdom
Stoke-on-Trent, Staffordshire ST4 6QG, United Kingdom
Belfast, BT16 1RH, United Kingdom